Oral ONC201

DRUG2 trials

Sponsors

Rutgers, The State University of New Jersey

Conditions

Solid TumorsUnspecified Adult Solid Tumor

Phase 1

Oral ONC201 in Treating Patients With Advanced Solid Tumors

CompletedNCT02250781

Rutgers, The State University of New JerseySolid Tumors

Start: 2015-01-12End: 2018-10-25Updated: 2019-05-22

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors

CompletedNCT02324621

Rutgers, The State University of New JerseyUnspecified Adult Solid Tumor

Start: 2015-02-20End: 2018-10-23Updated: 2019-05-22

Related Papers

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Journal for ImmunoTherapy of Cancer2019-05-2270 citations

Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

Journal of Clinical Oncology2018-05-202 citations

Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC).

Journal of Clinical Oncology2017-05-202 citations

Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients.

Journal of Clinical Oncology2017-05-201 citations

A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias

Blood2016-12-021 citations

Abstract 3012: ONC201 induces cell death in triple negative, BRCA1-deficient and non-triple negative breast cancer cells

Cancer Research2016-07-15

Abstract 3309: Novel small molecule ONC201 induces cell death and targets chemotherapy-resistant cancer stem-like cells in triple negative breast cancer

Cancer Research2016-07-15

Abstract 3087: Combination of ONC201 and bevacizumab significantly impacts colorectal cancer growth and metastasis <i>in vivo</i>

Cancer Research2016-07-15

Abstract 349: Structure-activity relationships and mechanistic analysis of analogues of the clinical-stage anti-cancer small molecule ONC201

Cancer Research2016-07-15

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

Pediatric Blood & Cancer2016-06-3096 citations

First-in-human trial of ONC201 in patients with refractory solid tumors.

Journal of Clinical Oncology2016-05-203 citations

Clinical activity of ONC201 in metastatic castrate resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2016-05-201 citations

Abstract C137: First-in-human dose escalation study of oral ONC201 in advanced solid tumors

Molecular Cancer Therapeutics2015-12-011 citations

First-in-human dose escalation study of oral ONC201 in advanced solid tumors.

Journal of Clinical Oncology2015-05-206 citations